Evidence map›Paper›PMID 32723485›Full record

ArticleClinical oncology (Royal College of Radiologists (Great Britain))2021

Optimising the Duration of Adjuvant Trastuzumab in Early Breast Cancer in the UK.

H M Earl, L Hiller, J Dunn, I Macpherson, D Rea, L Hughes-Davies, K McAdam, P Hall, J Mansi, D Wheatley and 8 more

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical oncology (Royal College of Radiologists (Great Britain)), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

H M EarlDepartment of Oncology, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK; Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; NIHR Cambridge Biomedical Research Centre, Cambridge, UK. Electronic address: hme22@cam.ac.uk.
L HillerWarwick Clinical Trials Unit, University of Warwick, Coventry, UK.
J DunnWarwick Clinical Trials Unit, University of Warwick, Coventry, UK.
I MacphersonUniversity of Glasgow, Institute of Cancer Sciences, Glasgow, UK.
D ReaCancer Research UK Clinical Trials Unit (CRCTU), Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.
L Hughes-DaviesDepartment of Oncology, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK; Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
K McAdamCambridge University Hospitals NHS Foundation Trust, Cambridge, UK; Department of Oncology, Peterborough City Hospital, North West Anglia NHS Foundation Trust, Peterborough, UK.
P HallEdinburgh University Cancer Research Centre, Institute of Genetics and Molecular Medicine, Western General Hospital, Edinburgh, UK.
J MansiDepartment of Medical Oncology, Guy's Hospital, Guy's and St Thomas' NHS Foundation Trust and King's College Medical School, London, UK.
D WheatleyRoyal Cornwall Hospitals NHS Trust, Truro, UK.
J E AbrahamDepartment of Oncology, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK; Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; NIHR Cambridge Biomedical Research Centre, Cambridge, UK.
C CaldasDepartment of Oncology, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK; Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; NIHR Cambridge Biomedical Research Centre, Cambridge, UK; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Cambridge, UK.
S GassonWarwick Clinical Trials Unit, University of Warwick, Coventry, UK.
E O'RiordanIndependent Cancer Patients' Voice, London, UK.
M WilcoxIndependent Cancer Patients' Voice, London, UK.
D MilesMount Vernon Cancer Centre, Northwood, UK.
D A CameronEdinburgh University Cancer Research Centre, Institute of Genetics and Molecular Medicine, Western General Hospital, Edinburgh, UK.
A WardleyThe NIHR Manchester Clinical Research Facility at The Christie, Manchester, UK; University of Manchester, Division of Cancer Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, Manchester, UK.

Funding

Cancer Research UK 16942Cancer Research UK 25354Cancer Research UK 29567Department of Health 06/303/98
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID32723485
PMCPMC7382576

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.